TYK2 and inflammatory bowel disease: Given the immunologic heterogeneity in SpA spectrum disorders and allied conditions, these findings provide a map toward therapy in SpA spectrum disease and why JAKi, especially with Tyk2 blockade in IBD, may not be a SpA disease spectrum panacea.